{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:46:30Z","timestamp":1767962790741,"version":"3.49.0"},"reference-count":58,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2014,10,15]],"date-time":"2014-10-15T00:00:00Z","timestamp":1413331200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0109992","type":"journal-article","created":{"date-parts":[[2014,10,21]],"date-time":"2014-10-21T16:00:32Z","timestamp":1413907232000},"page":"e109992","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":33,"title":["Serial Low Doses of Sorafenib Enhance Therapeutic Efficacy of Adoptive T Cell Therapy in a Murine Model by Improving Tumor Microenvironment"],"prefix":"10.1371","volume":"9","author":[{"given":"Hui-Yen","family":"Chuang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Fang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren-Shyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeng-Jong","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,10,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1089\/hum.2010.033","article-title":"Redirecting the immune response: role of adoptive T Cell therapy","volume":"21","author":"A Mondino","year":"2010","journal-title":"Hum Gene Ther"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.immunol.25.022106.141609","article-title":"Immunosuppressive strategies that are mediated by tumor cells","volume":"25","author":"GA Rabinovich","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev.immunol.25.022106.141527","article-title":"Improving T cell therapy for cancer","volume":"25","author":"AM Leen","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrc3298","article-title":"Evolutionary dynamics of carcinogenesis and why targeted therapy does not work","volume":"12","author":"RJ Gillies","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nbt.2284","article-title":"Combinatorial drug therapy for cancer in the post-genomic era","volume":"30","author":"B Al-Lazikani","year":"2012","journal-title":"Nat Biotechnol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"M Vanneman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1289\/ehp.824321","article-title":"Chemotherapy-induced immunosuppression","volume":"43","author":"L Rasmussen","year":"1982","journal-title":"Environ Health Perspect"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1089\/hum.2010.086","article-title":"Development of adoptive cell therapy for cancer: a clinical perspective","volume":"21","author":"RE Hawkins","year":"2010","journal-title":"Hum Gene Ther"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00262-008-0531-4","article-title":"Combined modality immunotherapy and chemotherapy: a new perspective","volume":"57","author":"R Ramakrishnan","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3626","article-title":"The secret ally: immunostimulation by anticancer drugs","volume":"11","author":"L Galluzzi","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"S Wilhelm","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1182\/blood-2007-02-075945","article-title":"Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses","volume":"111","author":"MM Hipp","year":"2008","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ejca.2010.11.021","article-title":"Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma","volume":"47","author":"A Busse","year":"2011","journal-title":"Eur J Cancer"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ijc.25674","article-title":"Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients","volume":"129","author":"IM Desar","year":"2011","journal-title":"Int J Cancer"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00262-008-0602-6","article-title":"Apoptosis of CD4+CD25high T cells in response to Sirolimus requires activation of T Cell Receptor and is modulated by IL-2","volume":"58","author":"KR Molhoek","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00262-012-1380-8","article-title":"Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma","volume":"62","author":"R Cabrera","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/1940-6207.CAPR-11-0308","article-title":"Immunomodulation of curcumin on adoptive therapy with T cell functional imaging in mice","volume":"5","author":"YF Chang","year":"2012","journal-title":"Cancer Prev Res (Phila)"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.biopha.2011.09.011","article-title":"Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-\u03baB expression in vitro and in vivo","volume":"66","author":"YC Kuo","year":"2012","journal-title":"Biomed Pharmacother"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/labinvest.2010.205","article-title":"Kinase inhibitor sorafenib modulates immunosuppressive cell populations in a murine liver cancer model","volume":"91","author":"M Cao","year":"2011","journal-title":"Lab Invest"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/ni.2088","article-title":"IDO: more than an enzyme","volume":"12","author":"WJ Chen","year":"2011","journal-title":"Nat Immuno"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/ng1001-117","article-title":"TGF-beta signaling in tumor suppression and cancer progression","volume":"29","author":"R Derynck","year":"2001","journal-title":"Nat Genet"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jhep.2011.01.047","article-title":"Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma","volume":"55","author":"WT Tai","year":"2011","journal-title":"J Hepatol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"9599","DOI":"10.1158\/0008-5472.CAN-10-1293","article-title":"Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects","volume":"70","author":"M Kujawski","year":"2010","journal-title":"Cancer Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"DI Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s00262-008-0505-6","article-title":"Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity","volume":"57","author":"C Menard","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s10495-006-9527-8","article-title":"Clearance of apoptotic and necrotic cells and its immunological consequences","volume":"11","author":"DV Krysko","year":"2006","journal-title":"Apoptosis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/jnci\/89.11.783","article-title":"Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity","volume":"89","author":"O Micheau","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1172\/JCI40269","article-title":"Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice","volume":"120","author":"R Ramakrishnan","year":"2010","journal-title":"J Clin Invest"},{"key":"ref29","first-page":"1645","article-title":"Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis","volume":"61","author":"S Lacour","year":"2001","journal-title":"Cancer Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/eji.200324181","article-title":"CD4+ CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative","volume":"34","author":"F Ghiringhelli","year":"2004","journal-title":"Eur J Immunol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"F Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1084\/jem.20062056","article-title":"Induced sensitization of tumor stroma leads to eradication of established cancer by T cells","volume":"204","author":"B Zhang","year":"2007","journal-title":"J Exp Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1172\/JCI34388","article-title":"Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice","volume":"118","author":"B Breart","year":"2008","journal-title":"J Clin Invest"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10555-011-9281-4","article-title":"Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy","volume":"30","author":"E Tartour","year":"2011","journal-title":"Cancer Metastasis Rev"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Y Huang","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/bcr3149","article-title":"Battle over CCL2 for control of the metastatic niche: neutrophils versus monocytes","volume":"14","author":"JB Mitchem","year":"2012","journal-title":"Breast Cancer Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1158\/0008-5472.CAN-09-2326","article-title":"CCL2 blockade augments cancer immunotherapy","volume":"70","author":"ZG Fridlender","year":"2010","journal-title":"Cancer Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s10585-012-9545-6","article-title":"CCL2 is critical for immunosuppression to promote cancer metastasis","volume":"30","author":"C Kudo-Saito","year":"2012","journal-title":"Clin Exp Metastasis"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1158\/0008-5472.CAN-04-2006","article-title":"Bcl-2 Overexpression Enhances Tumor-Specific T-Cell Survival","volume":"65","author":"J Charo","year":"2005","journal-title":"Cancer Res"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1084\/jem.184.3.1075","article-title":"The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand","volume":"184","author":"J O'Connell","year":"1996","journal-title":"J Exp Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"9817","DOI":"10.1158\/0008-5472.CAN-05-1462","article-title":"Addressing the &quot;Fas counterattack&quot; controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo","volume":"65","author":"AE Ryan","year":"2005","journal-title":"Cancer Res"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"H Yu","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1158\/1535-7163.MCT-09-0947","article-title":"Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3","volume":"9","author":"F Yang","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ijc.28362","article-title":"Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity","volume":"134","author":"ML Chen","year":"2014","journal-title":"Int J Cancer"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"JM Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"B Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"MS Brose","year":"2014","journal-title":"Lancet"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1158\/1078-0432.CCR-08-1141","article-title":"Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy","volume":"15","author":"NS Azad","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref49","first-page":"133","article-title":"Cutaneous side effects of new antitumor drugs: clinical features and management","volume":"109","author":"R Gutzmer","year":"2012","journal-title":"Dtsch Arztebl Int"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1111\/j.1365-4632.2012.05485.x","article-title":"Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma","volume":"52","author":"AK El Tal","year":"2013","journal-title":"Int J Dermatol"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Takahashi Y, Fukunishi S, Nishikawa T, Nouda S, Sasaki Y, <etal>et al<\/etal>.. (2013) Small-intestinal hemorrhage caused by treatment with sorafenib for hepatocellular carcinoma and diagnosed by capsule endoscopy. 45 Suppl 2 UCTN: E179\u2013180.","DOI":"10.1055\/s-0032-1326641"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"S Reagan-Shaw","year":"2008","journal-title":"FASEB J"},{"key":"ref53","first-page":"5348","article-title":"Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model","volume":"72","author":"P Kharaziha","year":"2012"},{"key":"ref54","article-title":"Use of VEGFR-2 Targeted Ultrasound Contrast Agent for the Early Evaluation of Response to Sorafenib in a Mouse Model of Hepatocellular Carcinoma","author":"M BaronToaldo","year":"2014","journal-title":"Mol Imaging Biol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/ijc.28506","article-title":"Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells","volume":"134","author":"A Hosoi","year":"2014","journal-title":"Int J Cancer"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/hep.26328","article-title":"Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells","volume":"57","author":"MF Sprinzl","year":"2013","journal-title":"Hepatology"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1158\/1078-0432.CCR-12-1626","article-title":"BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice","volume":"19","author":"C Liu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1172\/JCI66236","article-title":"Host immunity contributes to the anti-melanoma activity of BRAF inhibitors","volume":"123","author":"DA Knight","year":"2013","journal-title":"J Clin Invest"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0109992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T19:15:52Z","timestamp":1588965352000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0109992"}},"subtitle":[],"editor":[{"given":"Reiner Albert","family":"Veitia","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,10,15]]},"references-count":58,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0109992","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,15]]}}}